Literature DB >> 28933020

Deriving a management algorithm for emphysematous pyelonephritis: Can we rely on minimally invasive strategies or should we be opting for earlier nephrectomy?

Eve Boakes1, Deepak Batura2.   

Abstract

PURPOSE: To analyse the incidence and management of emphysematous pyelonephritis (EPN) in North West London and examine factors that influence immediate and 6-month outcomes with the aim of guiding future management.
METHODS: This work analyses EPN cases from the London North West Healthcare NHS Trust from October 2006 to July 2015 (population ≈ 850,000). Diagnosis and stage were confirmed by computed tomography (CT). Demographic, clinical, biochemical and microbiological characteristics were assessed. Treatment modalities were medical management, minimally invasive management (MIM) and surgical. Immediate and 6-month outcomes were analysed.
RESULTS: Thirteen cases were identified (f = 8, m = 5) from 5525 CT scans. EPN occurred in patients with diabetes mellitus (n = 11, 84.6%), hypertension (n = 10, 76.9%) or urinary tract calculi (n = 7, 53.85%). Unilateral EPN occurred predominantly (n = 11, 84.6%); 46.1% (n = 6) were class 1 or 2 and 53.8% (n = 7) class 3 or 4. Escherichia coli was most commonly cultured (n = 5, 38.46%). All patients received antibiotics, and ten cases required MIM. Two patients had a delayed nephrectomy, both survived. Mortality was 15.4% (n = 2, grade 1 and 3a), both died acutely post-MIM, neither underwent emergency nephrectomy. At 6 months, eight patients had ongoing renal impairment. No specific poor prognostic factors were identifiable.
CONCLUSIONS: Patients with low-grade EPN may also have a high mortality rate. In the two cases who died, earlier consideration for nephrectomy may have been prudent. It may be beneficial to have a low threshold for prompt emergency nephrectomy in severe cases and where MIM treatment has failed. We suggest a management algorithm to guide clinicians and minimise mortality.

Entities:  

Keywords:  Emphysematous; Infection; Kidney; Nephrectomy; Percutaneous nephrostomy; Pyelonephritis

Mesh:

Substances:

Year:  2017        PMID: 28933020     DOI: 10.1007/s11255-017-1706-8

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment.

Authors:  Sibhghatulla Shaikh; Jamale Fatima; Shazi Shakil; Syed Mohd Danish Rizvi; Mohammad Amjad Kamal
Journal:  Saudi J Biol Sci       Date:  2014-08-17       Impact factor: 4.219

2.  Key demographic characteristics of patients with bacteriuria due to extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in a multiethnic community, in North West London.

Authors:  G Gopal Rao; Deepak Batura; Neha Batura; Peder Bo Nielsen
Journal:  Infect Dis (Lond)       Date:  2015-06-16

3.  Clinical characteristics of emphysematous pyelonephritis.

Authors:  H J Tang; C M Li; M Y Yen; Y S Chen; S R Wann; H H Lin; S S Lee; Y C Liu
Journal:  J Microbiol Immunol Infect       Date:  2001-06       Impact factor: 4.399

4.  Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis.

Authors:  Ambar Khaira; Ankur Gupta; Devendra S Rana; Ashwini Gupta; Anil Bhalla; Dinesh Khullar
Journal:  Int Urol Nephrol       Date:  2009-04-30       Impact factor: 2.370

5.  Emphysematous pyelonephritis in diabetic patients.

Authors:  A R Pontin; R D Barnes; J Joffe; D Kahn
Journal:  Br J Urol       Date:  1995-01

Review 6.  Severe emphysematous pyelonephritis in a renal allograft: successful treatment with percutaneous drainage and antibiotics.

Authors:  Y W Chuang; C H Chen; C H Cheng; S W Hung; T M Yu; M J Wu; K H Shu
Journal:  Clin Nephrol       Date:  2007-07       Impact factor: 0.975

7.  Predictors of outcome in emphysematous pyelonephritis.

Authors:  Y L Wan; S K Lo; M J Bullard; P L Chang; T Y Lee
Journal:  J Urol       Date:  1998-02       Impact factor: 7.450

8.  Nephroureterectomy for emphysematous pyelonephritis: An aggressive approach is sometimes necessary. A case report and literature review.

Authors:  Gael R Nana; Andrew Brodie; Waseem Akhter; Omer Karim; Hanif Motiwala
Journal:  Int J Surg Case Rep       Date:  2015-03-28

Review 9.  Emphysematous pyelonephritis: Time for a management plan with an evidence-based approach.

Authors:  Omar M Aboumarzouk; Owen Hughes; Krishna Narahari; Richard Coulthard; Howard Kynaston; Piotr Chlosta; Bhaskar Somani
Journal:  Arab J Urol       Date:  2013-11-19

10.  Recommended Initial Antimicrobial Therapy for Emphysematous Pyelonephritis: 51 Cases and 14-Year-Experience of a Tertiary Referral Center.

Authors:  Yu-Chuan Lu; Jian-Hua Hong; Bing-Juin Chiang; Yuan-Hung Pong; Po-Ren Hsueh; Chao-Yuan Huang; Yeong-Shiau Pu
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more
  5 in total

Review 1.  Prevalence and Risk Factors of Mortality in Emphysematous Pyelonephritis Patients: A Meta-Analysis.

Authors:  Xuan Thai Ngo; Tuan Thanh Nguyen; Ryan W Dobbs; Minh Sam Thai; Duc Huy Vu; Le Quy Van Dinh; Khoa Quy; Hieu Trong Le; Tien-Dat Hoang; Hanh Thi Tuyet Ngo; Trinh Ngoc Khanh Van; Ho Yee Tiong; Huy Gia Vuong
Journal:  World J Surg       Date:  2022-07-08       Impact factor: 3.282

2.  Bilateral Emphysematous Pyelonephritis Associated with COVID Pneumonia: A Case Report.

Authors:  Slaviša Savić; Tadija Pejović; Nataša Savić
Journal:  Am J Case Rep       Date:  2022-06-27

Review 3.  A systematic review and meta-analysis of risk factors and treatment choices in emphysematous pyelonephritis.

Authors:  Rajeev Desai; Deepak Batura
Journal:  Int Urol Nephrol       Date:  2022-02-01       Impact factor: 2.370

Review 4.  Emphysematous pyelonephritis and cystitis: A case report and literature review.

Authors:  Shengxian Li; Jixue Wang; Jinghai Hu; Liang He; Chunxi Wang
Journal:  J Int Med Res       Date:  2018-06-19       Impact factor: 1.671

5.  Emphysematous pyelonephritis caused by C. glabrata.

Authors:  Eduardo Augusto Schutz; Ana Paula Zabott; Rubia Bethania Biela Boaretto; Gisele Toyama; Carlos Floriano de Morais; Juliana Gerhardt Moroni; Carla Sakuma de Oliveira
Journal:  J Bras Nefrol       Date:  2022 Jul-Sep
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.